On this page of StockholderLetter.com we present the latest annual shareholder letter from DiaMedica Therapeutics Inc. — ticker symbol DMAC. Reading current and past DMAC letters to shareholders can bring important insights into the investment thesis.

 •  3/28/2025 Letter Continued (Full PDF)
 •  4/4/2023 DMAC Stockholder Letter
 •  4/4/2024 DMAC Stockholder Letter
 •  More "Biotechnology" Category Stockholder Letters
 •  DMAC Benford's Law Stock Score = 92

DMAC Shareholder/Stockholder Letter Transcript:

2024 Annual Report &
2025 Annual General
Meeting Proxy Statement


Dear Shareholders,
As we reflect on DiaMedica   s journey throughout 2024, we are encouraged by the progress we
have made in advancing the treatment of acute ischemic stroke (AIS) and the exciting expansion
into preeclampsia (PE) with our therapeutic candidate, DM199 (rinvecalinase alfa). Our
dedication to innovation and patient-focused solutions continues to drive us forward. In 2024, we
successfully built upon the momentum gained from overcoming previous clinical hurdles,
expanded our leadership team, and strengthened our financial position to support our mission.
Progress in the ReMEDy2 Trial
A key focus this past year was the continued advancement of our ReMEDy2 Phase 2/3 pivotal
trial for AIS. With a protocol amendment to expand participant eligibility to certain additional
patients that we anticipate may perform well on DM199 treatment, we believe that we have
positioned ourselves to accelerate site activations and enrollment while optimizing trial
execution. Our rigorous approach to patient safety, enhanced trial design, and close collaboration
with our investigator network have positioned us to efficiently execute our ReMEDy2 trial. We
believe the additional work we undertook to ensure the safety and efficacy of DM199 has
bolstered confidence among our clinical partners.
This past year, we initiated multiple new clinical sites and streamlined patient recruitment, a
critical step in advancing the trial toward its next phase. We remain focused on efficiently
managing trial activities. Our goal is to bring DM199 closer to patients in need while
maintaining the highest scientific and ethical standards.
Expansion into Preeclampsia Phase 2 Trial
In addition to our progress in AIS, we were excited to announce our expansion into a Phase 2
clinical trial for the treatment of preeclampsia (PE). This important step broadens the potential
applications of DM199, leveraging the unique mechanism of DM199 to address another
significant unmet medical need. Preeclampsia remains a leading cause of maternal and fetal
morbidity, and we believe DM199 has the potential to provide a novel therapeutic approach for
this serious condition. Our team is dedicated to supporting our physician partners as they conduct
an initial proof-of-concept trial and ultimately to advancing the development of DM199 and this
trial with the same rigor and commitment to patient safety that has guided our work in AIS.
Leadership and Organizational Strength
We have also further strengthened our leadership team to ensure our progress continues
efficiently and effectively. We welcomed additional experienced professionals who bring deep
expertise in neurology, clinical operations and regulatory strategy. Their insights and leadership
will be instrumental as we advance through the critical next phases of development and navigate
the path toward potential regulatory approval.
We are also pleased to have recently announced the expansion of our Board of Directors with the
addition of Dan O'Connor. Dan brings a wealth of experience from his leadership at Ambryx
Biopharma Inc., which sold for $2 billion in 2024. His strategic vision and deep industry
knowledge will be invaluable as we continue to grow and execute our mission.

Our commitment to excellence extends beyond leadership to our entire team. The talent and
dedication of our organization remain the backbone of our ability to execute and drive
meaningful innovation in AIS and PE treatment.
Financial Stability and Growth
Financial discipline remains a cornerstone of our strategy. As of the close of 2024, we
maintained a strong cash position with an expected runway into the third quarter of 2026,
ensuring we are well-capitalized to continue executing on our clinical and operational objectives.
Our focus on prudent resource management allows us to sustain the momentum of our
ReMEDy2 trial and advance our new PE program while also exploring potential strategic
partnerships and funding opportunities to further strengthen our financial position.
While we are encouraged by our financial health, we remain committed to careful management
of resources to ensure long-term sustainability. Our disciplined approach to investment will
enable us to advance DM199 efficiently and maximize value for our shareholders.
Looking Ahead
The path forward for DM199 remains promising. With encouraging clinical data, a refined
strategy, and a committed team, we are optimistic about the future. We recognize that challenges
remain, but we are confident in our ability to navigate them with resilience and determination.
Your unwavering support as shareholders fuels our progress. We deeply appreciate your trust in
our mission and remain committed to keeping you informed as we advance toward our shared
goal of improving outcomes for AIS and PE patients.
Thank you for your continued confidence in DiaMedica. We look forward to another year of
progress, innovation, and impact.
Sincerely,
Sincerely,
Rick Pauls
President and Chief Executive Officer
James Parsons
Chairman of the Board

March 28, 2025
Dear Shareholders:
Together with our Board of Directors and the management team at DiaMedica Therapeutics Inc., we are
pleased to invite you to our 2025 Annual General Meeting of Shareholders, which will be held at our
corporate offices located at 301 Carlson Parkway, Suite 210, Minneapolis, Minnesota 55305, USA,
beginning at 9:00 a.m., CDT, on Thursday, May 15, 2025.
At the meeting, shareholders will be asked to consider and vote upon the following voting proposals:
(1) to elect seven persons to serve as directors until our next annual general meeting of shareholders or
until their respective successors are elected and qualified; (2) to appoint Baker Tilly US, LLP as our
independent registered public accounting firm for the fiscal year ending December 31, 2025 and to
authorize the Board of Directors to fix our independent registered public accounting firm   s remuneration;
and (3) to approve, on an advisory (non-binding) basis, our executive compensation.
The accompanying Notice of 2025 Annual General Meeting of Shareholders and proxy statement
describe these matters in more detail. We urge you to read this information carefully.
The Board of Directors recommends a vote: FOR each of the seven nominees for director named in the
proxy statement and FOR the approval of the other proposals being submitted to a vote of our
shareholders.
Voting your DiaMedica common shares is easily achieved without the need to attend the meeting in
person. Regardless of the number of shares you own, it is important that your shares be represented and
voted at the meeting. Therefore, we urge you to vote your shares via the Internet, by telephone, or by
promptly marking, dating, signing, and returning the proxy card. Voting over the Internet, by telephone,
or by written proxy will ensure that your shares are represented at the meeting.
On behalf of the Board of Directors, we thank you for your participation, investment and support.
Sincerely,
James Parsons
Chairman of the Board
Rick Pauls
President and Chief Executive Officer
You can help us make a difference by eliminating paper proxy materials. With your consent, we will
provide all future proxy materials electronically. Instructions for consenting to electronic delivery can be
found on your proxy card or at www.proxyvote.com. Your consent to receive shareholder materials
electronically will remain in effect until canceled.



 3/28/2025 Letter Continued (Full PDF)